MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment (NASDAQ:MGNX)
· seekingalpha.com
MacroGenics, Inc. downgraded to Hold after B7-H3 ADC setbacks; assess MGC026 phase 1 catalysts, pipeline risks, and liquidity outlook—click for this MGNX update.
This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you ...